Takeda Adds To Its Celiac Pipeline With Innate-Discovered Antibodies

 
• By Joseph Haas
  
GI disease
Takeda keeps investing in celiac disease as part of its GI therapy focus • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business